Clinical Trials Using Acetaminophen

Clinical trials are research studies that involve people. The clinical trials on this list are studying Acetaminophen. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-5 of 5
  • Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C / KEYNOTE-01C)

    The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with MK-5890 and MK-4830 in participants with advanced squamous or non-squamous NSCLC that have been previously treated with anti-PD-L1 therapy. This study is one of three pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01).
    Location: 3 locations

  • Assessing the Safety of Modified T Cells for Mesothelioma

    This phase I trial studies the effect and best dose of mesothelin-targeted chimeric antigen receptor (CAR)-T cells in treating patients with malignant pleural mesothelioma. T cells are a type of white blood cell that fight diseases like infections and cancer. Mesothelin (MSLN)-targeted CAR-T cell therapy, may activate the T cells to target and kill cancer cells that express mesothelin. MSLN-targeted CAR T cell therapy also includes an anti-PD1 component. Programmed cell death receptor 1 (PD1) is a protein that usually acts as a “brake” on the immune system. The anti-PD1 component blocks PD1, releasing the brakes and allowing T cells to target and destroy cancer cells. MSLN-targeted CAR T cell therapy may shrink or stabilize mesothelioma.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • S1916 Digital Medicine Program for Pain Control in Cancer Patients

    This is a feasibility study to assess the use of a Digital Medicine Program (consisting of an FDA-approved ingestible sensor co-encapsulated with oxycodone / acetaminophen (5 mg / 325 mg), a small wearable patch, and a mobile application) in cancer patients with metastatic disease experiencing uncontrolled pain.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • A Non-opioid Pain Control Regimen for Pain Management in Patients Undergoing Head and Neck Cancer Surgery

    This phase III trial studies how well a non-opioid pain control regimen administered before and during surgery works for pain management in patients undergoing head and neck cancer surgery. Opioids are a class of drugs that work in the brain to produce a variety of effects, including pain relief. In addition to controlling pain, opioids can make some people feel "high" and can be addictive. Acetaminophen, celecoxib, gabapentin, ketamine and lidocaine are non-opioid medications that when given before and during surgery, may improve post-surgery pain and / or decrease opioid consumption, which may relieve opioid related side effects and adverse symptoms, improve quality of life, and decrease the risk of chronic pain.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio

  • Biomarker Testing in Studying APAP-CYS Concentrations in Primary or Secondary Liver Cancer Patients with Non-acetaminophen Induced Liver Injury

    This phase IV trial studies APAP-CYS concentrations in primary or secondary liver cancer patients with non-acetaminophen induced liver injury after taking therapeutic doses of acetaminophen. This research may help doctors in the future better understand protein adduct concentrations in patient’s blood.
    Location: University of Colorado Hospital, Aurora, Colorado